Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(9):1166–1171. doi: 10.1054/bjoc.2001.1741

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

G Frasci 1, G Nicolella 1, P Comella 1, I Carreca 1, G DeCataldis 1, D Muci 1, C Brunetti 1, M Natale 1, F Piantedosi 1, A Russo 1, S Palmeri 1, G Comella 1, N Panza 1
PMCID: PMC2363878  PMID: 11336465

Abstract

The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin 40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2weekly, with G-CSF (5 μg/kg days 3–5) support, for a maximum of 12 weeks. 37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded, giving an 81% [95% CI = 65–92%] ORR. At a 13-month (range, 4–26) median follow-up, median progression-free and overall survival were 8 months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4 neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line approaches. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: small cell lung cancer, weekly chemotherapy, paclitaxel, topotecan

Full Text

The Full Text of this article is available as a PDF (71.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akerley W., Glantz M., Choy H., Rege V., Sambandam S., Joseph P., Yee L., Rodrigues B., Wingate P., Leone L. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998 Jan;16(1):153–158. doi: 10.1200/JCO.1998.16.1.153. [DOI] [PubMed] [Google Scholar]
  2. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., Giaccone G., Schaefer B., Wanders J., Verweij J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997 May;15(5):2090–2096. doi: 10.1200/JCO.1997.15.5.2090. [DOI] [PubMed] [Google Scholar]
  3. Burris H. A., 3rd, Awada A., Kuhn J. G., Eckardt J. R., Cobb P. W., Rinaldi D. A., Fields S., Smith L., Von Hoff D. D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs. 1994 Aug;5(4):394–402. doi: 10.1097/00001813-199408000-00002. [DOI] [PubMed] [Google Scholar]
  4. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  5. Ettinger D. S., Finkelstein D. M., Sarma R. P., Johnson D. H. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995 Jun;13(6):1430–1435. doi: 10.1200/JCO.1995.13.6.1430. [DOI] [PubMed] [Google Scholar]
  6. Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., Tong W., Norton L., Spriggs D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997 Jan;15(1):187–192. doi: 10.1200/JCO.1997.15.1.187. [DOI] [PubMed] [Google Scholar]
  7. Frasci G., Panza N., Comella P., Cartení G., Guida T., Nicolella G. P., Natale M., Lombardi R., Apicella A., Pacilio C. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol. 1999 Mar;10(3):355–358. doi: 10.1023/a:1008301222560. [DOI] [PubMed] [Google Scholar]
  8. Glisson B. S., Kurie J. M., Perez-Soler R., Fox N. J., Murphy W. K., Fossella F. V., Lee J. S., Ross M. B., Nyberg D. A., Pisters K. M. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug;17(8):2309–2315. doi: 10.1200/JCO.1999.17.8.2309. [DOI] [PubMed] [Google Scholar]
  9. Haas N. B., LaCreta F. P., Walczak J., Hudes G. R., Brennan J. M., Ozols R. F., O'Dwyer P. J. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res. 1994 Mar 1;54(5):1220–1226. [PubMed] [Google Scholar]
  10. Hainsworth J. D., Burris H. A., 3rd, Morrissey L. H., Greco F. A. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. Cancer. 1999 Mar 1;85(5):1179–1185. [PubMed] [Google Scholar]
  11. Hainsworth J. D., Gray J. R., Stroup S. L., Kalman L. A., Patten J. E., Hopkins L. G., Thomas M., Greco F. A. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol. 1997 Dec;15(12):3464–3470. doi: 10.1200/JCO.1997.15.12.3464. [DOI] [PubMed] [Google Scholar]
  12. Hochster H., Liebes L., Speyer J., Sorich J., Taubes B., Oratz R., Wernz J., Chachoua A., Raphael B., Vinci R. Z. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 1994 Mar;12(3):553–559. doi: 10.1200/JCO.1994.12.3.553. [DOI] [PubMed] [Google Scholar]
  13. Johnson B. E., Grayson J., Makuch R. W., Linnoila R. I., Anderson M. J., Cohen M. H., Glatstein E., Minna J. D., Ihde D. C. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol. 1990 Mar;8(3):396–401. doi: 10.1200/JCO.1990.8.3.396. [DOI] [PubMed] [Google Scholar]
  14. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1998. CA Cancer J Clin. 1998 Jan-Feb;48(1):6–29. doi: 10.3322/canjclin.48.1.6. [DOI] [PubMed] [Google Scholar]
  15. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  16. O'Reilly S., Fleming G. F., Barker S. D., Walczak J. R., Bookman M. A., McGuire W. P., 3rd, Schilder R. J., Alvarez R. D., Armstrong D. K., Horowitz I. R. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997 Jan;15(1):177–186. doi: 10.1200/JCO.1997.15.1.177. [DOI] [PubMed] [Google Scholar]
  17. Schiller J. H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., Johnson D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol. 1996 Aug;14(8):2345–2352. doi: 10.1200/JCO.1996.14.8.2345. [DOI] [PubMed] [Google Scholar]
  18. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
  19. Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufmann S. H. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993 Feb 17;85(4):271–291. doi: 10.1093/jnci/85.4.271. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES